Patents by Inventor Ivan A. Belashov

Ivan A. Belashov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-HIV peptides
    Patent number: 11186614
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: November 30, 2021
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • ANTI-HIV PEPTIDES
    Publication number: 20200115418
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 16, 2020
    Applicants: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • Anti-HIV peptides
    Patent number: 10538556
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex
    Publication number: 20150268247
    Abstract: The present invention relates to the production of an ElonginB/ElonginC/Vif/CBF? tetramer complex comprising full-length Vif protein. The present invention provides an assay for screening any agent that inhibits the ability of Vif to bind with Cul5. The invention provides an agent identified by the screening methods and methods of treatment using the identified agent. The invention also provides compositions that inhibit Vif-Cul5 binding based upon regions identified in Vif and Cul5 that mediate Vif-Cul5 binding.
    Type: Application
    Filed: October 22, 2013
    Publication date: September 24, 2015
    Inventors: Joseph E. Wedekind, Jason D. Salter, Geoffrey M. Lippa, Ivan A. Belashov